Science.Online
Publisher and Institutes
Akademie Verlag
Deutsches Institut für Urbanistik
Oldenbourg Wissenschaftsverlag
Walter de Gruyter
Schattauer
You are here: Home :: Area NEM :: Medical science :: Human medicine :: Internal medicine
 
N. Lubenow, A. Greinacher

Hirudins in the treatment of heparin-induced thrombocytopenia and in thrombosis prophylaxis

Approved indications for the recombinant hirudins lepirudin (Refludan) und desirudin (Revasc) are therapy of heparin-induced thrombocytopenia (HIT) and thrombosis prophylaxis following knee or hip replacement surgery. Kidney function dependent pharmacokinetics and their capability of inducing antibodies directed against hirudin are characteristic of this class of drugs. However, close dose-monitoring allows safe and effective use of both compounds. While lepirudin is used widely, besides danaparoid, for treatment of HIT, desirudin has not yet been widely accepted for thrombosis prophylaxis following knee or hip replacement surgery.

Hämostaseologie, Schattauer

Print ISSN: 0720-9355
Volume: 22, 01/2002
Pages: 44 - 54

Show full article (external site)

Show all available items of this journal